AS03 adjuvant: Clinical Trials

5 trials of AS03 adjuvant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 terminated. 5 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 4, Terminated 1
Phase 12Completed 1, Terminated 1

Follow AS03 adjuvant: new trials by email Literature Review of AS03 adjuvant trials Research Report on AS03 adjuvant

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety Immunogenicity Study of MT-2766 in Japanese Adults(COVID-19)
MT-2766 High dose (3.75 µg), Placebo, MT-2766 Low dose - SARS-CoV-2 Infection
Phase 1 / Phase 2TerminatedMedicago1282021-10-022023-11-07
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older
FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3 - Influenza, Human
Phase 2CompletedGlaxoSmithKline8332021-03-162023-10-10
Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59
VN, IN, dk/BANG - Influenza A Virus, H5N1 Subtype
Phase 2CompletedBiomedical Advanced Research and Development Authority7202018-03-152020-07-14
Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)
H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant - Influenza A Virus, H5N1 Subtype
Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)502013-07-012019-02-12
Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant
H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant - Influenza
Phase 1 / Phase 2CompletedNational Institute of Allergy and Infectious Diseases (NIAID)432012-03-202019-02-26

Conditions studied

Influenza in Birds (2)  ·  Influenza, Human (2)  ·  COVID-19 (1)  ·  Virus Diseases (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  Biomedical Advanced Research and Development Authority (1)  ·  GlaxoSmithKline (1)  ·  Medicago (1)

Countries

United States (4)  ·  Japan (1)

Top investigators

John S Tsang, Ph.D. (1)  ·  Nadine Rouphael, MD (1)

Results publications

PMID 30302282, PMID 34174187, PMID 39702896

NIH funding

U19AI090023 (1)